沛嘉醫療-B(09996.HK):ReachTactile™機器人輔助TAVR系統成功完成首例患者治療
格隆匯4月6日丨沛嘉醫療-B(09996.HK)發佈公告,2025年4月2日,公司完成ReachTactile™機器人輔助經導管主動脈瓣置換(“TAVR”)系統首次人體臨牀試驗的首例患者治療。手術由廈門大學附屬心血管病醫院的王焱教授及其團隊完成,利用ReachTactile™機器人輔助TAVR系統爲一名重度主動脈瓣狹窄患者植入TaurusElite™經導管主動脈瓣膜。
ReachTactileTM是公司內部研發的機器人輔助TAVR系統,爲TAVR治療提供創新、高性價比的解決方案。可模塊化移動的設計適配於傳統的血管介入導管室,允許一名心臟病專家以亞毫米級的精度操作多臺器械。其搭載的力傳感機制可提供即時觸覺反饋,有助於在複雜的血管條件下的器械導航通行。基於主從控制佈局能夠有效降低術者輻射暴露等職業健康風險。同時,基於以太網的遠程控制功能可實現跨地域手術操作及操作培訓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.